ALLO
Allogene Therapeutics, Inc.
Price Chart
Latest Quote
$1.87
Current Price| Previous Close | $1.84 |
| Open | $1.79 |
| Day High | $1.93 |
| Day Low | $1.71 |
| Volume | 11,392,157 |
Stock Information
| Shares Outstanding | 224.73M |
| Total Debt | $85.14M |
| Cash Equivalents | $252.19M |
| Net Income | $-212.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $420.25M |
| EPS (TTM) | $-0.98 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.21 |
| Debt to Earnings | -0.35 |
| Current Ratio | 8.54 |
| Quick Ratio | 8.23 |
| Avg Revenue Growth | -25.00% |
| Profit Margin | -1170863.64% |
| Return on Equity | -61.01% |
| Avg FCF Growth | -0.64% |
| FCF Yield | -47.83% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $1.87 | 11,399,200 |
| 2026-01-30 | $1.84 | 16,758,200 |
| 2026-01-29 | $1.59 | 7,382,900 |
| 2026-01-28 | $1.45 | 6,789,800 |
| 2026-01-27 | $1.53 | 6,544,000 |
| 2026-01-26 | $1.51 | 8,188,500 |
| 2026-01-23 | $1.72 | 7,538,600 |
| 2026-01-22 | $1.72 | 5,943,300 |
| 2026-01-21 | $1.60 | 4,294,700 |
| 2026-01-20 | $1.57 | 4,831,500 |
| 2026-01-16 | $1.63 | 4,731,800 |
| 2026-01-15 | $1.61 | 5,638,900 |
| 2026-01-14 | $1.70 | 4,631,500 |
| 2026-01-13 | $1.64 | 4,992,700 |
| 2026-01-12 | $1.67 | 8,560,000 |
| 2026-01-09 | $1.71 | 12,310,500 |
| 2026-01-08 | $1.49 | 3,090,900 |
| 2026-01-07 | $1.49 | 4,254,300 |
| 2026-01-06 | $1.41 | 5,210,300 |
| 2026-01-05 | $1.35 | 2,422,700 |
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
đ° Latest News
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-01-26T14:40:01Z
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
Motley Fool âĸ 2026-01-21T22:58:39Z
January 2026 Penny Stock Spotlight: Three Promising Picks
Simply Wall St. âĸ 2026-01-12T12:05:08Z
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Zacks âĸ 2026-01-09T14:40:02Z
December 2025 Penny Stocks Worth Watching
Simply Wall St. âĸ 2025-12-12T18:05:07Z
November 2025's Promising Penny Stocks To Watch
Simply Wall St. âĸ 2025-11-12T18:05:26Z
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
Zacks âĸ 2025-11-07T16:20:00Z
Allogene Therapeutics Inc (ALLO) Q3 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2025-11-07T05:11:45Z
Allogene Therapeutics: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-06T21:26:37ZTVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Zacks âĸ 2025-10-14T15:24:00Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $22,000 | $95,000 | $156,000 | $114,089,000 |
| Operating Revenue | $22,000 | $95,000 | $156,000 | $114,089,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $181,000 | $0 | - | - |
| Total Expenses | $257,504,000 | $314,587,000 | $335,692,000 | $294,281,000 |
| Other Income Expense | $-19,637,000 | $-31,080,000 | $-9,444,000 | $-3,573,000 |
| Other Non Operating Income Expenses | $-3,920,000 | $-17,835,000 | $-9,444,000 | $-3,573,000 |
| Net Non Operating Interest Income Expense | $19,972,000 | $18,307,000 | $4,566,000 | $1,714,000 |
| Interest Expense Non Operating | $181,000 | $0 | - | - |
| Operating Expense | $257,504,000 | $314,587,000 | $335,692,000 | $294,281,000 |
| General And Administrative Expense | $65,205,000 | $71,673,000 | $79,305,000 | $74,105,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Net Interest Income | $19,972,000 | $18,307,000 | $4,566,000 | $1,714,000 |
| Interest Income | $20,153,000 | $18,307,000 | $4,566,000 | $1,714,000 |
| Normalized Income | $-245,173,570 | $-314,020,000 | $-340,414,000 | $-182,051,000 |
| Net Income From Continuing And Discontinued Operation | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Total Operating Income As Reported | $-273,199,000 | $-327,737,000 | $-335,536,000 | $-180,192,000 |
| Net Income Common Stockholders | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Net Income | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Net Income Including Noncontrolling Interests | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Net Income Continuous Operations | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Pretax Income | $-257,147,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Special Income Charges | $-15,717,000 | $-13,245,000 | - | - |
| Interest Income Non Operating | $20,153,000 | $18,307,000 | $4,566,000 | $1,714,000 |
| Operating Income | $-257,482,000 | $-314,492,000 | $-335,536,000 | $-180,192,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.32 | $-2.09 | $-2.32 | $-1.89 |
| Basic EPS | $-1.32 | $-2.09 | $-2.32 | $-1.89 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-3,300,570 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-227,610,000 | $-299,821,000 | $-321,241,000 | $-169,738,000 |
| Total Unusual Items | $-15,717,000 | $-13,245,000 | - | - |
| Total Unusual Items Excluding Goodwill | $-15,717,000 | $-13,245,000 | - | - |
| Reconciled Depreciation | $13,639,000 | $14,199,000 | $14,295,000 | $10,454,000 |
| EBITDA (Bullshit earnings) | $-243,327,000 | $-313,066,000 | $-321,241,000 | $-169,738,000 |
| EBIT | $-256,966,000 | $-327,265,000 | $-335,536,000 | $-180,192,000 |
| Diluted Average Shares | $194,811,756 | $156,931,778 | $143,147,165 | $135,820,386 |
| Basic Average Shares | $194,811,756 | $156,931,778 | $143,147,165 | $135,820,386 |
| Diluted NI Availto Com Stockholders | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Tax Provision | $443,000 | $0 | - | $0 |
| Impairment Of Capital Assets | $15,717,000 | $13,245,000 | - | - |
| Research And Development | $192,299,000 | $242,914,000 | $256,387,000 | $220,176,000 |
| Selling General And Administration | $65,205,000 | $71,673,000 | $79,305,000 | $74,105,000 |
| Other Gand A | $65,205,000 | $71,673,000 | $79,305,000 | $74,105,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $422,179,000 | $512,233,000 | $666,882,000 | $925,200,000 |
| Total Assets | $548,710,000 | $642,837,000 | $821,579,000 | $1,050,828,000 |
| Total Non Current Assets | $245,324,000 | $183,722,000 | $292,755,000 | $579,505,000 |
| Other Non Current Assets | $33,390,000 | $16,896,000 | $19,856,000 | $16,107,000 |
| Investmentin Financial Assets | $80,673,000 | $0 | $59,151,000 | $352,179,000 |
| Current Assets | $303,386,000 | $459,115,000 | $528,824,000 | $471,323,000 |
| Other Current Assets | $10,910,000 | $10,418,000 | $11,504,000 | $14,021,000 |
| Cash Cash Equivalents And Short Term Investments | $292,476,000 | $448,697,000 | $517,320,000 | $457,302,000 |
| Cash And Cash Equivalents | $75,218,000 | $83,155,000 | $61,904,000 | $173,314,000 |
| Cash Equivalents | - | $78,536,000 | - | - |
| Cash Financial | - | $4,619,000 | - | - |
| Prepaid Assets | - | - | - | $14,021,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $90,756,000 | $95,121,000 | $101,124,000 | $73,129,000 |
| Long Term Debt And Capital Lease Obligation | $83,247,000 | $88,346,000 | $95,122,000 | $69,929,000 |
| Current Debt And Capital Lease Obligation | $7,509,000 | $6,775,000 | $6,002,000 | $3,200,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $126,531,000 | $130,604,000 | $154,697,000 | $125,628,000 |
| Total Non Current Liabilities Net Minority Interest | $91,008,000 | $93,525,000 | $100,969,000 | $77,721,000 |
| Other Non Current Liabilities | $7,761,000 | $5,179,000 | $5,847,000 | $7,792,000 |
| Current Liabilities | $35,523,000 | $37,079,000 | $53,728,000 | $47,907,000 |
| Payables And Accrued Expenses | $15,868,000 | $17,553,000 | $29,696,000 | $28,425,000 |
| Payables | $5,394,000 | $5,897,000 | $13,890,000 | $10,255,000 |
| Accounts Payable | $5,394,000 | $5,897,000 | $13,890,000 | $10,255,000 |
| Other Current Liabilities | - | $86,000 | - | - |
| Current Deferred Liabilities | - | $86,000 | $95,000 | $156,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $422,179,000 | $512,233,000 | $666,882,000 | $925,200,000 |
| Total Equity Gross Minority Interest | $422,179,000 | $512,233,000 | $666,882,000 | $925,200,000 |
| Stockholders Equity | $422,179,000 | $512,233,000 | $666,882,000 | $925,200,000 |
| Gains Losses Not Affecting Retained Earnings | $-89,000 | $-955,000 | $-9,926,000 | $-2,567,000 |
| Other Equity Adjustments | $-89,000 | $-955,000 | $-9,926,000 | $-2,567,000 |
| Retained Earnings | $-1,819,823,000 | $-1,562,233,000 | $-1,234,968,000 | $-894,554,000 |
| Long Term Equity Investment | $0 | $3,645,000 | $17,317,000 | $30,199,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $212,210,597 | $168,642,238 | $144,438,304 | $142,623,065 |
| Share Issued | $212,210,597 | $168,642,238 | $144,438,304 | $142,623,065 |
| Tangible Book Value | $422,179,000 | $512,233,000 | $666,882,000 | $925,200,000 |
| Invested Capital | $422,179,000 | $512,233,000 | $666,882,000 | $925,200,000 |
| Working Capital | $267,863,000 | $422,036,000 | $475,096,000 | $423,416,000 |
| Capital Lease Obligations | $90,756,000 | $95,121,000 | $101,124,000 | $73,129,000 |
| Total Capitalization | $422,179,000 | $512,233,000 | $666,882,000 | $925,200,000 |
| Additional Paid In Capital | $2,241,879,000 | $2,075,252,000 | $1,911,632,000 | $1,822,179,000 |
| Capital Stock | $212,000 | $169,000 | $144,000 | $142,000 |
| Common Stock | $212,000 | $169,000 | $144,000 | $142,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $83,247,000 | $88,346,000 | $95,122,000 | $69,929,000 |
| Current Capital Lease Obligation | $7,509,000 | $6,775,000 | $6,002,000 | $3,200,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,146,000 | $12,665,000 | $17,935,000 | $16,126,000 |
| Current Accrued Expenses | $10,474,000 | $11,656,000 | $15,806,000 | $18,170,000 |
| Investments And Advances | $80,673,000 | $3,645,000 | $76,468,000 | $382,378,000 |
| Available For Sale Securities | $80,673,000 | - | $59,151,000 | $352,179,000 |
| Net PPE | $131,261,000 | $163,181,000 | $196,431,000 | $181,020,000 |
| Accumulated Depreciation | $-62,538,000 | $-51,084,000 | $-36,885,000 | $-23,361,000 |
| Gross PPE | $193,799,000 | $214,265,000 | $233,316,000 | $204,381,000 |
| Leases | $108,127,000 | $108,621,000 | $108,550,000 | $108,353,000 |
| Other Properties | $76,800,000 | $96,860,000 | $116,193,000 | $87,696,000 |
| Machinery Furniture Equipment | $8,872,000 | $8,784,000 | $8,545,000 | $8,293,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $217,258,000 | $365,542,000 | $455,416,000 | $283,988,000 |
| Current Deferred Revenue | - | $86,000 | $95,000 | $156,000 |
| Construction In Progress | - | $0 | $28,000 | $39,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-200,994,000 | $-239,249,000 | $-225,710,000 | $-206,258,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-200,300,000 | $-237,733,000 | $-220,519,000 | $-184,812,000 |
| Cash Flow From Continuing Operating Activities | $-200,300,000 | $-237,733,000 | $-220,519,000 | $-184,812,000 |
| Operating Gains Losses | $1,688,000 | $10,672,000 | $12,883,000 | $4,090,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-694,000 | $-1,516,000 | $-5,191,000 | $-21,446,000 |
| Investing Cash Flow | $75,688,000 | $163,289,000 | $106,159,000 | $163,655,000 |
| Cash Flow From Continuing Investing Activities | $75,688,000 | $163,289,000 | $106,159,000 | $163,655,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $112,047,000 | $91,112,000 | $0 | $0 |
| Financing Cash Flow | $116,675,000 | $95,695,000 | $2,950,000 | $11,963,000 |
| Cash Flow From Continuing Financing Activities | $116,675,000 | $95,695,000 | $2,950,000 | $11,963,000 |
| Net Other Financing Charges | $2,280,000 | - | - | - |
| Net Common Stock Issuance | $112,047,000 | $91,112,000 | $0 | $0 |
| Common Stock Issuance | $112,047,000 | $91,112,000 | $0 | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $85,510,000 | $93,447,000 | $72,196,000 | $183,606,000 |
| Beginning Cash Position | $93,447,000 | $72,196,000 | $183,606,000 | $192,800,000 |
| Changes In Cash | $-7,937,000 | $21,251,000 | $-111,410,000 | $-9,194,000 |
| Proceeds From Stock Option Exercised | $2,348,000 | $4,583,000 | $2,950,000 | $11,963,000 |
| Net Investment Purchase And Sale | $76,382,000 | $164,805,000 | $111,350,000 | $202,811,000 |
| Sale Of Investment | $437,857,000 | $603,434,000 | $359,459,000 | $728,394,000 |
| Purchase Of Investment | $-361,475,000 | $-438,629,000 | $-248,109,000 | $-525,583,000 |
| Net PPE Purchase And Sale | $-694,000 | $-1,516,000 | $-5,191,000 | $-21,446,000 |
| Purchase Of PPE | $-694,000 | $-1,516,000 | $-5,191,000 | $-21,446,000 |
| Change In Working Capital | $-24,799,000 | $-21,307,000 | $3,897,000 | $-31,949,000 |
| Change In Other Working Capital | $-20,773,000 | $-3,000 | $-21,000 | $-38,297,000 |
| Change In Other Current Liabilities | $-6,048,000 | $-6,613,000 | $-1,882,000 | $910,000 |
| Change In Other Current Assets | $4,279,000 | $-1,455,000 | $-3,334,000 | $-646,000 |
| Change In Payables And Accrued Expense | $-1,765,000 | $-14,325,000 | $6,617,000 | $2,885,000 |
| Change In Accrued Expense | $-1,262,000 | $-6,823,000 | $1,749,000 | $3,652,000 |
| Change In Payable | $-503,000 | $-7,502,000 | $4,868,000 | $-767,000 |
| Change In Account Payable | $-503,000 | $-7,502,000 | $4,868,000 | $-767,000 |
| Change In Prepaid Assets | $-492,000 | $1,086,000 | $2,517,000 | $3,199,000 |
| Other Non Cash Items | $5,250,000 | $6,581,000 | $2,329,000 | $-73,129,000 |
| Stock Based Compensation | $51,743,000 | $65,951,000 | $83,600,000 | $80,818,000 |
| Asset Impairment Charge | $17,674,000 | $20,245,000 | - | - |
| Amortization Of Securities | $-8,348,000 | $-6,809,000 | $2,891,000 | $6,955,000 |
| Deferred Tax | $443,000 | $0 | - | $0 |
| Deferred Income Tax | $443,000 | $0 | - | $0 |
| Depreciation Amortization Depletion | $13,639,000 | $14,199,000 | $14,295,000 | $10,454,000 |
| Depreciation And Amortization | $13,639,000 | $14,199,000 | $14,295,000 | $10,454,000 |
| Earnings Losses From Equity Investments | $1,688,000 | $10,672,000 | $12,883,000 | $4,090,000 |
| Net Income From Continuing Operations | $-257,590,000 | $-327,265,000 | $-340,414,000 | $-182,051,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-17,710,000 |
| Purchase Of Business | - | $0 | $0 | $-17,710,000 |
| Amortization Cash Flow | - | - | $0 | $0 |
| Amortization Of Intangibles | - | - | $0 | $0 |
| Depreciation | - | - | $14,295,000 | $10,454,000 |